Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023)

Cellectis (CLLS) recorded quarterly Income from Non-Controlling Interests of -$4.9 million in Q2 2023, down 101.39% quarter-over-quarter from -$2.4 million in Q1 2023, and down 1075.1% on a YoY basis from $506000.0 in Q2 2022.

Cellectis (CLLS) Income from Non-Controlling Interests (2015 - 2023) Analysis & Trends

Cellectis' Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$4.9 million for Q2 2023.

  • In Q2 2023, Income from Non-Controlling Interests fell 1075.1% year-over-year to -$4.9 million; the TTM figure through Mar 2024 stood at -$4.9 million (up 23.93% YoY), while the FY2023 annual figure was -$7.4 million, up 6.46% from the prior year.
  • Income from Non-Controlling Interests was -$4.9 million for Q2 2023 at Cellectis, down from -$2.4 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $506000.0 in Q2 2022 to a low of -$6.1 million in Q4 2020.
  • Historically, Income from Non-Controlling Interests has averaged -$3.0 million across 5 years, with a median of -$3.1 million in 2019.
  • The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests jumped 129.92% in 2022, then plunged 1075.1% in 2023.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$3.9 million in 2019, then sank by 55.09% to -$6.1 million in 2020, then surged by 49.63% to -$3.1 million in 2021, then soared by 43.45% to -$1.7 million in 2022, then slumped by 182.91% to -$4.9 million in 2023.
  • The last three Income from Non-Controlling Interests figures came in at -$4.9 million (Q2 2023), -$2.4 million (Q1 2023), and -$1.7 million (Q4 2022), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -13.75 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Cellectis 17.40 Bn 17.21 Bn - -

Historic Data

Download Data
DateValue
Jun 30, 2023 -4.93 Mn
Mar 31, 2023 -2.45 Mn
Dec 31, 2022 -1.74 Mn
Sep 30, 2022 -2.80 Mn
Jun 30, 2022 506,000.00
Mar 31, 2022 -2.85 Mn
Dec 31, 2021 -3.08 Mn
Sep 30, 2021 -2.66 Mn
Jun 30, 2021 -1.69 Mn
Mar 31, 2021 -3.48 Mn
Dec 31, 2020 -6.12 Mn
Sep 30, 2020 -3.31 Mn
Jun 30, 2020 -3.59 Mn
Mar 31, 2020 -3.48 Mn
Dec 31, 2019 -3.95 Mn
Sep 30, 2019 -3.49 Mn
Jun 30, 2019 -3.19 Mn
Mar 31, 2019 -2.48 Mn
Dec 31, 2018 -2.99 Mn
Sep 30, 2018 -2.51 Mn